

Reboxetine

General:

Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and attention-deficit hyperactivity disorder. It is a norepinephrine reuptake inhibitor (NRI) but it does not inhibit the reuptake of serotonin, therefore it can be safely combined with a selective serotonin reuptake inhibitor.

Common side effects of reboxetine are consistent with its anticholinergic properties, and include: dry mouth, constipation, headache, drowsiness, dizziness, excessive sweating and insomnia. Hypertension has been observed infrequently. Because of its reliance on CYP3A4, reboxetine O-desethylation is markedly inhibited by papaverine and ketoconazole. Reboxetine also is an intermediate-level inhibitor of P-glycoprotein, which gives it the potential to interact with cyclosporine, tacrolimus, paroxetine, sertraline, quinidine, fluoxetine, fluvoxamine. The potency and duration of the effects of benzodiazepines can be increased because reboxetine interferes with their excretion.

Material: 1 ml serum

TAT: 7-10 days*

Method: LCMS

Units: µg/l

Ref.- range: 60.0 - 350.0

For complete list of laboratory test offered at Freiburg Medical Laboratory, please visit <http://www.fml-dubai.com/parameter-listings/>